Ben Venue Resumes Limited Production - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Ben Venue Resumes Limited Production

ePT--the Electronic Newsletter of Pharmaceutical Technology

Ben Venue Laboratories has resumed production on a limited number of manufacturing lines in the company’s Bedford, Ohio, facilities. The company reported last week that it continues to make progress toward upgrading the company’s manufacturing facilities and anticipates that production will resume on additional lines as corrective measures to address facility and equipment issues are implemented. For most of the products it manufacturers, however, supplies will not be available for at least several months, according to the company.

Late last year, Ben Venue Laboratories announced that it was extending its voluntary suspension of manufacturing at its Bedford facility. The company had originally announced the suspension on Nov. 19, 2011, and announced the extension of the suspension on Dec. 23, 2011. Ben Venue had suspended manufacturing at the Bedford facility after an internal review indicated that routine preventive maintenance and requalification of some manufacturing equipment were overdue. These issues also were noted in inspection findings by FDA, EMA, and other global regulatory agencies. Ben Venue’s operations in Bedford include sterile injectable facilities with aseptic filling, lyophilization, and cytotoxic manufacturing in four factories.

In an Oct. 16, 2012, press release, Ben Venue says it continues to work in close collaboration with FDA and other global regulatory agencies. Following FDA’s inspection of Ben Venue’s manufacturing operations in May 2011, the company began the implementation of a remediation effort and says it has invested more than $300 million to upgrade its facilities by making necessary improvements and changes to its processes to resolve the manufacturing-related issues that resulted in the voluntary shutdown last year.

See related stories

EMA Says Ben Venue's Anticancer Drugs Should be Manufactured in Another Facility (ePT)

Ben Venue Continues Suspension of Manufacturing Activity at Ohio Facility (ePT)


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here